Fenofibrate lowers atypical sphingolipids in plasma of dyslipidemic patients: A novel approach for treating diabetic neuropathy?
- 3 April 2015
- journal article
- research article
- Published by Elsevier BV in Journal of Clinical Lipidology
- Vol. 9 (4), 568-575
- https://doi.org/10.1016/j.jacl.2015.03.011
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- FenofibrateDrugs, 2011
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)European Heart Journal, 2011
- Lipoprotein Management in Patients With Cardiometabolic RiskJournal of the American College of Cardiology, 2008
- Molecular identification of nicotinic acid receptorBiochemical and Biophysical Research Communications, 2003
- Molecular Identification of High and Low Affinity Receptors for Nicotinic AcidPublished by Elsevier BV ,2003
- Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final ReportCirculation, 2002
- A Human Peroxisome‐Proliferator‐Activated Receptor‐γ is Activated by Inducers of Adipogenesis, Including Thiazolidinedione DrugsEuropean Journal of Biochemistry, 1996
- The RXR heterodimers and orphan receptorsCell, 1995
- cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptorBiochemistry, 1993
- Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferatorsNature, 1990